MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Neurology
Neurology

Fenebrutinib Achieves 69% Reduction in New Brain Lesions for Relapsing Multiple Sclerosis: Insights from the FENopta Phase 2 Trial

MedXY Editorial TeamDec 23, 2025
fenebrutinibmultiple sclerosisneuroimmunology

Highlights

Efficacy Results

Fenebrutinib demonstrated a 69% relative reduction in the total number of new T1 gadolinium-enhancing (Gd+) lesions compared to placebo (p=0.0022) at 12 weeks.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials

NeurologyNov 2, 2026

Elevated Risk of Inflammatory Bowel Disease Following Anti-CD20 Therapy in Multiple Sclerosis Patients: Insights from a Swedish Population-Based Cohort

NeurologyOct 30, 2026

Long-Term Clinical Outcomes of Zika-Related Microcephaly: Insights from the First Five Years of Life

NeurologyNov 5, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story